1. The physiological response to exercise involves coordinated adrenergic receptor activation across multiple organ systems. Which of the following most accurately maps the receptor-level events mediating the cardiovascular and metabolic adaptations to vigorous exercise?

• A) During vigorous exercise: (1) Cardiac beta-1 receptor activation by sympathetic NE and circulating epinephrine increases heart rate (positive chronotropy via increased SA node If current), contractility (positive inotropy via L-type calcium channel phosphorylation), and relaxation speed (positive lusitropy via phospholamban phosphorylation increasing SERCA2a activity), increasing cardiac output from 5 L/min at rest to 20-25 L/min at maximal effort; (2) Alpha-1 receptor activation in splanchnic, cutaneous, and renal vascular beds produces vasoconstriction, redirecting blood flow from these beds to exercising skeletal muscle; (3) Beta-2 receptor activation in skeletal muscle vasculature and coronary arteries produces vasodilation, increasing oxygen and substrate delivery; (4) Beta-2 receptor activation in liver and muscle produces glycogenolysis (releasing glucose for oxidative metabolism); (5) Alpha-2 receptor activation on pancreatic beta cells reduces insulin secretion (appropriate because skeletal muscle glucose uptake during exercise is insulin-independent via contraction-stimulated GLUT4 translocation); (6) Beta-3 receptor activation in adipose tissue promotes lipolysis, providing free fatty acids as oxidative fuel for sustained aerobic effort; (7) Beta-2 receptor stimulation of the Na+/K+-ATPase in skeletal muscle temporarily shifts potassium intracellularly, but sustained exercise eventually raises serum potassium from muscle K+ efflux.
• B) During exercise, the sympathetic nervous system is completely suppressed and the parasympathetic system is the primary cardiovascular driver -- vagal withdrawal (not sympathetic activation) accounts for the initial heart rate increase during exercise; the heart rate increase from 60 to 90 bpm at the onset of moderate exercise is entirely from vagal withdrawal; sympathetic activation occurs only during near-maximal exercise (heart rates above 140 bpm); the metabolic adaptations (glycogenolysis, lipolysis) are mediated by exercise-induced local tissue factors (lactate, adenosine, CO2) rather than adrenergic receptor activation.
• C) Beta-1 receptor activation during exercise acts exclusively on the SA node to increase heart rate -- the increase in contractility during exercise is mediated entirely by the Frank-Starling mechanism (increased end-diastolic volume from venous return) without any beta-1 inotropic contribution; beta-2 receptors mediate all metabolic adaptations (glycogenolysis and lipolysis) and all vascular responses (both vasoconstriction and vasodilation); alpha receptors have no role in exercise physiology.
• D) The exercise response demonstrates why non-selective beta-blockade (propranolol) significantly limits exercise capacity while cardioselective beta-1 blockade (metoprolol, bisoprolol) causes less impairment: non-selective blockade prevents all of: beta-1-mediated cardiac output increase, beta-2-mediated skeletal muscle vasodilation, beta-2-mediated glycogenolysis and lipolysis, and beta-2-mediated K+/Na+ pump activation; cardioselective beta-1 blockade limits cardiac chronotropy and inotropy but preserves beta-2-mediated vasodilation, glycogenolysis, lipolysis, and metabolic substrate mobilization -- explaining why athletes and patients requiring beta-blockade tolerate cardioselective agents better than non-selective agents during exercise.
• E) During exercise, alpha-1 receptor activation in the heart is the primary mediator of increased contractility -- cardiac alpha-1 receptors are expressed on ventricular myocytes and when activated by exercise-released NE and epinephrine produce IP3-mediated calcium release from the SR that is additive with beta-1-mediated L-type calcium current; athletes with high sympathetic tone achieve their superior cardiac output during exercise primarily through alpha-1-mediated contractility rather than beta-1 receptor activation; this explains why alpha-1 blockers substantially limit exercise capacity in competitive athletes.

2. The concept of adrenergic receptor cross-talk with the renin-angiotensin-aldosterone system (RAAS) is fundamental to understanding hypertension pharmacotherapy. Which of the following most accurately describes the multiple points of intersection between the adrenergic system and the RAAS, and explains why the combination of a beta-blocker and an ACE inhibitor or ARB is mechanistically synergistic in heart failure?

• A) Adrenergic-RAAS cross-talk occurs at a single point -- angiotensin II directly activates beta-1 adrenergic receptors on cardiac myocytes; ACE inhibitors reduce angiotensin II, reducing beta-1 activation; beta-blockers competitively block the residual angiotensin II at beta-1 receptors; the two drug classes are synergistic because each blocks the same pathway (angiotensin II-beta-1 receptor signaling) by a different mechanism.
• B) The adrenergic-RAAS intersection occurs at multiple points: (1) Sympathetic beta-1 activation of JG cells directly stimulates renin release (increasing angiotensin II and aldosterone); (2) Angiotensin II (via AT1 receptors on sympathetic nerve terminals) facilitates NE release by enhancing calcium influx at the presynaptic terminal -- a positive feedback loop where sympathetic activation increases RAAS activation, and RAAS activation further increases sympathetic NE release; (3) Angiotensin II at AT1 receptors in the CNS (circumventricular organs, NTS, hypothalamus) increases central sympathetic outflow; (4) Aldosterone acts on CNS mineralocorticoid receptors to increase sympathetic outflow and sensitize baroreceptors; (5) NE and epinephrine activate adrenal cortex alpha-1 receptors to increase aldosterone secretion independent of angiotensin II; (6) In heart failure, both sympathetic activation and RAAS activation are pathologically elevated and mutually reinforcing -- beta-blockers interrupt the sympathetic limb (reducing renin release, reducing cardiac beta-1 stimulation, reducing central sympathetic outflow) while ACE inhibitors/ARBs interrupt the RAAS limb (reducing angiotensin II-mediated presynaptic NE facilitation, reducing aldosterone, reducing central RAAS-driven sympathetic activation) -- the two classes interrupt a mutually reinforcing neurohormonal cycle at complementary points, producing synergistic benefit exceeding either drug alone.
• C) The RAAS and adrenergic system are completely independent signaling pathways with no cross-talk -- the combination of beta-blocker plus ACE inhibitor is additive rather than synergistic because both drugs lower blood pressure by independent mechanisms (cardiac output reduction vs RAAS blockade) that happen to add together; the claim of synergy is a marketing distinction without mechanistic basis; in heart failure, the benefit of combining the two classes reflects statistical pooling of two independent beneficial effects rather than any pharmacodynamic interaction between the pathways.
• D) The primary adrenergic-RAAS cross-talk is at the adrenal cortex: circulating NE activates adrenal cortex alpha-1 receptors to stimulate aldosterone synthesis independently of the renin-angiotensin pathway; in primary aldosteronism, the elevated aldosterone is entirely adrenergic in origin; alpha-1 blockers (doxazosin) reduce aldosterone in primary aldosteronism by blocking adrenal cortex alpha-1 receptors; beta-blockers have no effect on aldosterone because the JG cell renin-release pathway is not significant in humans.
• E) Adrenergic-RAAS cross-talk is limited to the kidney where sympathetic alpha-1 activation of the efferent arteriole increases glomerular filtration pressure, activating the macula densa tubuloglomerular feedback mechanism to release renin; beta-blockers do not reduce renin because JG cells express only alpha-1 receptors (not beta-1); the combination benefit of beta-blocker plus ACE inhibitor in heart failure is explained entirely by their independent effects on cardiac remodeling, not by RAAS modulation.

3. Signal transduction downstream of beta-adrenergic receptor activation involves a sequence of molecular events that can be selectively targeted. Which of the following most accurately describes the PKA-dependent phosphorylation events mediating cardiac inotropy and lusitropy, and explains the concept of phosphodiesterase-mediated cAMP compartmentation?

• A) Beta-1 receptor activation -> Gs -> adenylyl cyclase -> cAMP -> PKA activation -> four major cardiac PKA substrates: (1) L-type calcium channels (Cav1.2): PKA phosphorylation of the alpha-1C subunit increases channel open probability and mean open time, increasing calcium influx during the action potential plateau -- the primary mediator of beta-adrenergic positive inotropy; (2) Phospholamban (PLB): at rest, unphosphorylated PLB tonically inhibits SERCA2a in the SR; PKA phosphorylation of PLB at Ser16 removes this inhibition, increasing SERCA2a activity and accelerating SR calcium reuptake during diastole -- increasing lusitropy (relaxation speed) AND increasing SR calcium load for the next beat (supporting sustained inotropy); (3) Ryanodine receptor (RyR2): PKA phosphorylation at Ser2808 increases RyR2 open probability, amplifying calcium-induced calcium release from the SR during the action potential; (4) Troponin I: PKA phosphorylation of cardiac troponin I reduces the calcium sensitivity of the thin filament, promoting faster cross-bridge detachment and relaxation (additional lusitropy); cAMP compartmentation: cAMP generated by beta-1 receptor activation is spatially confined to microdomains near the receptor by phosphodiesterases (particularly PDE3 and PDE4) that hydrolyze cAMP before it diffuses to distant cellular compartments -- this compartmentation allows receptor-specific signaling and explains why milrinone (PDE3 inhibitor) and rolipram/roflumilast (PDE4 inhibitor) amplify only specific subsets of beta-adrenergic signaling rather than all cAMP-dependent pathways simultaneously.
• B) Beta-1 receptor activation produces cardiac inotropy entirely through increased calcium influx via L-type channels -- phospholamban phosphorylation, ryanodine receptor phosphorylation, and troponin I phosphorylation are redundant mechanisms that contribute negligibly to the inotropic response; PKA substrates beyond L-type calcium channels have been identified in vitro but have not been confirmed to be physiologically significant in the intact human heart; cAMP compartmentation is a cell biology concept with no pharmacological relevance because PDE inhibitors (milrinone) produce identical signaling to beta-1 receptor activation without any compartmentation effects.
• C) The PKA phosphorylation cascade in cardiac inotropy is: beta-1 activation -> Gs -> increased cAMP -> PKA -> phosphorylation of the Na+/K+-ATPase (primary inotropic mechanism, reducing intracellular sodium and increasing sodium gradient for NCX-mediated calcium extrusion, paradoxically increasing calcium efflux and reducing intracellular calcium loading); the positive inotropic effect of beta-1 stimulation therefore requires intact Na+/K+-ATPase activity -- explaining why digoxin (which inhibits Na+/K+-ATPase) is actually a beta-1 agonist at the molecular level, producing its inotropic effect by mimicking PKA-mediated Na+/K+-ATPase phosphorylation.
• D) cAMP compartmentation is achieved by A-kinase anchoring proteins (AKAPs) rather than phosphodiesterases -- AKAPs tether PKA catalytic subunits to specific subcellular locations near their target substrates, ensuring that cAMP generated at the receptor membrane directly activates the locally anchored PKA; PDE inhibitors have no effect on cAMP compartmentation because compartmentation is a structural protein-mediated phenomenon; milrinone (PDE3 inhibitor) and the beta-1 agonist dobutamine produce identical PKA activation patterns because both equally elevate total cellular cAMP without any compartment-specific distinction.
• E) The four PKA substrates in cardiac cells (L-type calcium channel, phospholamban, ryanodine receptor, troponin I) are each phosphorylated in a specific sequence determined by their proximity to adenylyl cyclase: L-type channels are phosphorylated first (adjacent to the receptor), then phospholamban (SR membrane), then RyR2 (SR lumen facing), then troponin I (myofilament, most distant); this ordered phosphorylation sequence means that the inotropic effect (L-type Ca2+ channel) precedes the lusitropic effect (troponin I) by several seconds during beta-1 stimulation; drugs that extend the duration of beta-1 signaling (PDE inhibitors) therefore produce disproportionate inotropy relative to lusitropy because the early-phosphorylated inotropic substrate benefits more from prolonged cAMP elevation.

4. Alpha-2 adrenergic receptors are expressed in the central nervous system at several distinct anatomical locations. Which of the following most accurately maps the CNS alpha-2 receptor locations and the clinical effects produced by agonists at each site, explaining the therapeutic versatility of alpha-2 agonist drugs?

• A) CNS alpha-2 receptor locations and agonist effects: (1) Nucleus tractus solitarius (NTS) and rostral ventrolateral medulla (RVLM): alpha-2 agonism reduces tonic sympathetic preganglionic outflow -- the antihypertensive mechanism of clonidine and methyldopa (via alpha-methylnorepinephrine); (2) Locus coeruleus (LC): the principal noradrenergic nucleus of the brainstem; alpha-2 agonism reduces LC firing rate, producing sedation, anxiolysis, and attenuation of sympathetically mediated arousal -- the mechanism of dexmedetomidine ICU sedation and clonidine sedation; additionally, LC alpha-2 activation reduces sympathetically mediated opioid withdrawal symptoms (adrenergic hyperactivity -- tachycardia, hypertension, piloerection, diaphoresis, anxiety) -- the basis for using clonidine in opioid withdrawal management; (3) Prefrontal cortex (PFC) postsynaptic alpha-2A receptors: agonism by guanfacine and clonidine at postsynaptic alpha-2A receptors on PFC pyramidal neurons closes HCN channels (reducing the If current that reduces PFC signal-to-noise), strengthening persistent firing and improving working memory, impulse control, and sustained attention -- the mechanism of guanfacine and clonidine benefit in ADHD and PTSD; (4) Spinal cord dorsal horn: intrathecal alpha-2 agonists (clonidine, dexmedetomidine) produce analgesia by presynaptically inhibiting nociceptive afferent terminal calcium channels (reducing substance P and glutamate release) and postsynaptically hyperpolarizing dorsal horn neurons via GIRK channels -- the mechanism of intrathecal/epidural clonidine analgesia.
• B) CNS alpha-2 receptors exist only in the locus coeruleus and have a single clinical effect: sedation; all other effects attributed to CNS alpha-2 agonism (antihypertension, analgesia, ADHD treatment) are peripheral effects from alpha-2 receptors outside the brain; dexmedetomidine produces sedation via locus coeruleus alpha-2 activation while producing its cardiovascular effects via peripheral (vascular, cardiac) alpha-2 receptors; the concept of different clinical effects from different CNS alpha-2 locations is a theoretical distinction without clinical validation.
• C) CNS alpha-2 receptor agonists produce diametrically opposite effects in different brain regions: LC activation by alpha-2 agonists produces arousal and hypervigilance (not sedation) because the locus coeruleus is the alertness center; RVLM alpha-2 activation produces tachycardia (not bradycardia) because the RVLM is the cardiac accelerator center; the sedating and antihypertensive properties of clonidine and dexmedetomidine are paradoxical and result from a non-adrenergic mechanism -- imidazoline I1 receptor activation in the reticular activating system -- not from alpha-2 receptor activation in the CNS.
• D) CNS alpha-2 receptor agonism at the NTS/RVLM reduces sympathetic outflow (antihypertensive, used by clonidine and methyldopa); at the locus coeruleus produces sedation and attenuates opioid withdrawal (used by clonidine and dexmedetomidine); at PFC alpha-2A receptors improves executive function and impulse control (used by guanfacine for ADHD and PTSD); at spinal dorsal horn produces analgesia (used by intrathecal clonidine); the therapeutic versatility of alpha-2 agonists reflects this rich CNS distribution with distinct functional consequences at each locus -- the same drug can be simultaneously antihypertensive, sedating, analgesic, and pro-cognitive depending on the relative contribution of each site to the drug's overall effect profile.
• E) Guanfacine and clonidine treat ADHD through the same mechanism as methylphenidate -- they block the norepinephrine transporter (NET) in the prefrontal cortex, increasing synaptic NE concentrations; the alpha-2A receptor mechanism is a secondary effect that occurs only at doses above the therapeutic ADHD range; at standard ADHD doses, guanfacine and clonidine function as selective NET inhibitors indistinguishable pharmacologically from atomoxetine; the postsynaptic alpha-2A HCN channel closure mechanism is relevant only at doses used for hypertension management.

5. The beta-2 adrenergic receptor mediates bronchodilation through a PKA-dependent mechanism, but chronic activation by long-acting beta-2 agonists leads to tolerance. Which of the following most accurately explains the molecular events of beta-2 receptor desensitization and the pharmacological rationale for combining long-acting beta-2 agonists with inhaled corticosteroids?

• A) Beta-2 receptor desensitization occurs through GRK-beta-arrestin-mediated internalization: agonist-occupied beta-2 receptors are phosphorylated by GRK2 (and GRK3 at high agonist concentrations) on serine and threonine residues in the third intracellular loop and C-terminal tail; phosphorylated receptors recruit beta-arrestin-2, which: (1) sterically prevents Gs coupling (uncoupling -- reduced cAMP generation from the same receptor occupancy); (2) acts as a clathrin/AP2 adaptor driving receptor internalization into endosomes within 15-30 minutes; internalized receptors are either recycled to the surface (short agonist exposure) or trafficked to lysosomes for degradation (prolonged exposure -- downregulation); with chronic LABA use, net surface receptor density decreases (downregulation), reducing the maximum bronchodilatory response; ICS rationale: glucocorticoid receptor activation by ICS increases transcription of the ADRB2 gene (beta-2 adrenergic receptor gene) via glucocorticoid response elements in the promoter; increased ADRB2 mRNA and protein synthesis replenishes surface receptor density, counteracting LABA-induced downregulation; additionally, GR activation increases Gs protein alpha subunit expression and reduces GRK2 expression -- enhancing coupling efficiency and reducing the rate of desensitization; this dual mechanism (receptor resynthesis + improved coupling) is the molecular basis for the synergistic ICS-LABA combination (Advair/Symbicort/Breo) -- the ICS keeps the beta-2 receptor system sensitive to the LABA, preventing tolerance and allowing sustained bronchodilation.
• B) Beta-2 receptor desensitization occurs exclusively through receptor internalization without any change in coupling efficiency -- the GRK-beta-arrestin pathway does not uncouple receptors from Gs but only removes them from the surface; the reduction in bronchodilatory response from chronic LABA use reflects purely reduced receptor density with no component of reduced coupling efficiency; ICS prevents desensitization by blocking GRK2 transcription (glucocorticoids repress the GRK2 gene promoter) without any effect on ADRB2 gene transcription.
• C) Beta-2 receptor tolerance with chronic LABA use is entirely reversible within 24 hours of stopping the LABA -- GRK-mediated phosphorylation is removed by constitutive phosphatases within hours of agonist removal; receptor internalization is completely reversed by recycling within 24 hours; clinical tolerance to LABAs therefore does not accumulate over weeks of therapy; the ICS combination with LABAs is required by guidelines not to prevent beta-2 receptor tolerance but to provide anti-inflammatory effects that prevent airway remodeling independent of bronchodilation.
• D) The GRK-beta-arrestin desensitization mechanism does not apply to beta-2 receptors in airway smooth muscle -- it applies only to cardiac beta-1 receptors; bronchial beta-2 receptor tolerance from chronic LABA use is mediated by receptor post-translational modification (palmitoylation of the cysteine residue in the fourth transmembrane domain) that locks the receptor in an inactive conformation; ICS reverses this palmitoylation by activating depalmitoylase enzymes via the glucocorticoid receptor, restoring receptor sensitivity.
• E) ICS synergizes with LABAs exclusively through anti-inflammatory mechanisms -- the molecular interaction between glucocorticoid receptors and beta-2 adrenergic receptors at the transcriptional level is a theoretical concept without in vivo validation; the clinical benefit of ICS-LABA over either agent alone in asthma and COPD reflects the additive anti-inflammatory effect of ICS combined with the additive bronchodilatory effect of LABA; no direct molecular interaction between glucocorticoid signaling and beta-2 receptor expression or sensitivity has been demonstrated in human airway tissue.

6. VMAT2 (vesicular monoamine transporter 2) is essential for catecholamine storage in sympathetic nerve terminals. Which of the following most accurately explains the physiological consequences of VMAT2 inhibition by reserpine and distinguishes reserpine depletion from postganglionic sympathetic denervation in terms of pharmacological responses?

• A) Reserpine irreversibly inhibits VMAT2, preventing catecholamine uptake from cytoplasm into storage vesicles -- cytoplasmic catecholamines are then degraded by intraneuronal MAO; vesicular stores are progressively depleted over hours to days as vesicle contents are not replenished; the sympathetic nerve terminal remains structurally intact (the axon, terminal, and NET are all preserved) but cannot accumulate and release catecholamines normally; consequences: profound sympatholytic effects (hypotension, bradycardia, sedation from CNS monoamine depletion -- reserpine depletes central dopamine, NE, and serotonin in addition to peripheral NE); pharmacological distinction from denervation: (1) Reserpine-treated terminals cannot respond to indirect-acting sympathomimetics (tyramine, amphetamine) because indirect agents require vesicular NE to displace -- with vesicles depleted, tyramine finds no NE to release; (2) Direct-acting sympathomimetics (phenylephrine, epinephrine) retain full efficacy because postsynaptic receptors are intact and NOT supersensitive (the NET is intact and reuptake is preserved); (3) Denervation (permanent axon loss) produces receptor upregulation and supersensitivity to direct-acting agents, and also abolishes indirect sympathomimetic response; reserpine depletion does not produce receptor supersensitivity because the nerve terminal is intact -- the distinction between pharmacological denervation (reserpine) and anatomical denervation (axon cutting) is both mechanistically and pharmacologically important.
• B) Reserpine and postganglionic denervation produce identical pharmacological responses at the effector organ -- both abolish responses to indirect sympathomimetics and both produce denervation supersensitivity to direct-acting agents; the distinction between reserpine depletion and anatomical denervation is academic and has no practical pharmacological significance; reserpine produces denervation supersensitivity because VMAT2 inhibition causes the vesicle protein complex (including NET) to degrade, functionally removing the nerve terminal.
• C) Reserpine produces a temporary depletion of catecholamine stores that fully recovers within 24 hours of stopping the drug -- the VMAT2 inhibition is reversible and vesicular stores are replenished rapidly by ongoing catecholamine synthesis; the clinical antihypertensive effect of reserpine requires daily dosing to maintain continuous VMAT2 inhibition; reserpine-depleted terminals remain fully responsive to indirect sympathomimetics because new NE synthesis (from ongoing tyrosine hydroxylase activity) continuously refills vesicles even while VMAT2 is inhibited.
• D) VMAT2 inhibition by reserpine depletes vesicular catecholamines and makes terminals unresponsive to indirect sympathomimetics; however, reserpine also blocks the norepinephrine transporter (NET) directly -- this dual mechanism (VMAT2 inhibition plus NET blockade) prevents both vesicular storage and reuptake; the NET blockade component explains why reserpine-treated patients show enhanced responses to directly injected catecholamines (no reuptake to remove them) that is equivalent in magnitude to the denervation supersensitivity seen after anatomical sympathectomy.
• E) Reserpine specifically depletes epinephrine from the adrenal medulla but has no effect on norepinephrine stores in sympathetic nerve terminals -- VMAT2 in sympathetic terminals transports only norepinephrine and dopamine while VMAT1 (in the adrenal medulla) transports epinephrine; reserpine selectively inhibits VMAT1 (adrenal) over VMAT2 (sympathetic terminals); the antihypertensive effect of reserpine therefore reflects adrenal medullary epinephrine depletion rather than peripheral sympathetic NE depletion.

7. The NET (norepinephrine transporter) is the primary mechanism for terminating adrenergic neurotransmission. Which of the following most accurately compares the pharmacological profiles of three NET-inhibiting drugs -- cocaine, desipramine, and atomoxetine -- in terms of selectivity, clinical application, and mechanism-based adverse effects?

• A) Cocaine blocks NET, DAT (dopamine transporter), and SERT (serotonin transporter) with approximately equal potency -- this non-selective monoamine reuptake inhibition produces: sympathomimesis (NET blockade accumulating NE at adrenergic receptors: tachycardia, hypertension, vasoconstriction, mydriasis); euphoriant reward (DAT blockade in the mesolimbic nucleus accumbens accumulating dopamine: the primary mechanism of cocaine addiction); serotonergic effects (SERT blockade: contributing to mood effects); cocaine also blocks voltage-gated sodium channels (local anesthetic mechanism); cocaine's short duration of action (30-60 minutes) reflects its rapid hepatic hydrolysis by plasma esterases and liver esterases; clinical use: limited to topical local anesthesia for ENT procedures (uniquely combines vasoconstriction from alpha-1 activation with local anesthesia) and as a diagnostic test for Horner syndrome (NET blockade at iris dilator terminals); desipramine (tricyclic antidepressant) blocks NET with substantially greater selectivity over DAT and SERT than cocaine but also blocks muscarinic M1/M2, histamine H1, and alpha-1 adrenergic receptors -- producing anticholinergic adverse effects (dry mouth, constipation, urinary retention, tachycardia), sedation (H1 blockade), and orthostatic hypotension (alpha-1 blockade) in addition to its antidepressant NET/SERT inhibition; cardiac conduction toxicity from sodium channel blockade is the life-threatening adverse effect of TCA overdose; atomoxetine (Strattera) is a highly selective NET inhibitor (minimal DAT and SERT activity) -- used for ADHD (increasing PFC NE availability for alpha-2A-mediated executive function improvement) and occasionally for depression; adverse effects from selective NET blockade: tachycardia, mild hypertension, insomnia, decreased appetite, and urinary hesitancy (alpha-1-mediated internal sphincter contraction from increased NE); atomoxetine carries a black box warning for suicidality in pediatric patients; unlike stimulant ADHD medications, atomoxetine is non-scheduled (low abuse potential because minimal DAT activity means minimal mesolimbic dopamine reward).
• B) Cocaine, desipramine, and atomoxetine are all equally selective NET inhibitors -- they differ only in their half-lives (cocaine 30-60 minutes, desipramine 12-24 hours, atomoxetine 4-5 hours) and their routes of administration; the anticholinergic side effects of desipramine are from its NET inhibition causing excess NE to activate presynaptic alpha-2 heteroreceptors on cholinergic terminals, reducing ACh release from parasympathetic nerves throughout the body; the abuse potential difference between cocaine and atomoxetine reflects only their half-lives -- with a half-life equal to cocaine, atomoxetine would have identical abuse potential.
• C) Atomoxetine and desipramine are equally selective NET inhibitors with identical clinical profiles; the only difference between them is that desipramine has two additional tricyclic ring structures while atomoxetine has a phenoxypropylamine structure; these ring structures have no pharmacological significance beyond determining molecular weight and distribution volume; the superior tolerability of atomoxetine over desipramine is entirely pharmacokinetic (better renal clearance, no active metabolites) with no pharmacodynamic component.
• D) NET inhibition by any drug class always produces identical cardiovascular effects regardless of selectivity -- cocaine, desipramine, and atomoxetine all produce equivalent degrees of tachycardia, hypertension, and cardiac arrhythmia because these effects are determined entirely by the degree of NET blockade, which is similar for all three drugs at clinically used doses; the additional cardiovascular toxicity of cocaine overdose reflects only its local anesthetic sodium channel blockade, not any difference in adrenergic receptor activation.
• E) The primary clinical use of NET inhibition is cardiovascular -- all three NET inhibitors (cocaine, desipramine, atomoxetine) are primarily used to increase norepinephrine levels in the heart and blood vessels to treat orthostatic hypotension; the CNS effects (euphoria for cocaine, antidepressant for desipramine, ADHD for atomoxetine) are off-target side effects of the primary cardiovascular NET inhibitor mechanism; droxidopa (a norepinephrine prodrug) is preferred over NET inhibitors for orthostatic hypotension because it increases NE availability without the cardiovascular adverse effects of NET blockade.

8. The dopamine receptor system is integral to cardiovascular and renal pharmacology. Which of the following most accurately distinguishes the D1-like from D2-like receptor families and explains the pharmacological relevance of fenoldopam as a selective D1 agonist in hypertensive emergencies?

• A) D1-like receptors (D1, D5): couple to Gs, stimulate adenylyl cyclase, increase cAMP -- expressed in renal vasculature, mesangial cells, and proximal tubular cells; D1 activation in the kidney produces: afferent and efferent arteriolar vasodilation (increasing renal blood flow), inhibition of proximal tubule Na+/H+ exchanger and Na+/K+-ATPase (producing natriuresis and diuresis), and inhibition of aldosterone secretion; D1 activation in the mesenteric and coronary vasculature produces vasodilation; D2-like receptors (D2, D3, D4): couple to Gi, inhibit adenylyl cyclase, activate GIRK channels -- expressed in presynaptic adrenergic terminals (reducing NE release), pituitary lactotrophs (inhibiting prolactin secretion), chemoreceptor trigger zone (CTZ; mediating the antiemetic target of metoclopramide and domperidone), and striatum/limbic system (mediating the antipsychotic target of haloperidol and the antiparkinsonian target of bromocriptine); Fenoldopam mechanism: selective D1 receptor agonist with no significant D2, alpha, or beta adrenergic activity; produces renal and mesenteric vasodilation, improving renal perfusion and GFR while lowering blood pressure; the renal-sparing properties (maintaining or improving GFR and sodium excretion during BP lowering) distinguish fenoldopam from other antihypertensives (nitroprusside, nicardipine) that lower BP without directly protecting renal perfusion; particularly valuable in hypertensive emergency with concurrent acute kidney injury.
• B) D1 and D2 receptors both couple to Gs and produce identical second messenger profiles -- the distinction between them is purely anatomical (D1 is postsynaptic, D2 is presynaptic); fenoldopam selectively activates both D1 and D2 receptors in the kidney, producing vasodilation through D1-Gs-cAMP and NE release inhibition through D2 presynaptic blockade; the combination of direct vasodilation and reduced NE release is why fenoldopam is more effective than selective D1 agents alone.
• C) Fenoldopam is a selective dopamine D1 agonist used for hypertensive emergencies with specific renal protective advantages over other IV antihypertensives -- its D1-Gs-cAMP mechanism in renal vasculature and tubular cells produces natriuresis and maintained GFR while lowering systemic blood pressure; the drug has no D2, alpha, or beta adrenergic activity; clinical use is limited by reflex tachycardia (from baroreceptor-mediated sympathetic activation in response to vasodilation -- the same reflex as with any peripheral vasodilator) and by the need for continuous IV infusion; its renal protective properties have made it a useful alternative to nitroprusside in hypertensive emergencies complicated by renal insufficiency.
• D) The D1-like and D2-like receptor families have opposite effects on dopamine synthesis: D1 activation increases tyrosine hydroxylase transcription (promoting catecholamine synthesis) while D2 activation (via Gi) inhibits tyrosine hydroxylase (reducing catecholamine synthesis); fenoldopam by selectively activating D1 receptors would therefore increase catecholamine synthesis -- an undesirable effect in hypertensive emergency; the standard clinical recommendation is to combine fenoldopam with a D2 agonist (bromocriptine) to counterbalance the D1-mediated catecholamine synthesis stimulation.
• E) Fenoldopam is now obsolete and has been replaced by clevidipine (an ultra-short-acting dihydropyridine CCB) for all indications including hypertensive emergencies with renal insufficiency -- recent comparative trials showed no renal outcome benefit from fenoldopam over clevidipine; the D1 receptor hypothesis for renal protection in acute hypertension was disproven in 2018; current guidelines no longer recommend fenoldopam for any indication.